<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572817</url>
  </required_header>
  <id_info>
    <org_study_id>IRC-005</org_study_id>
    <nct_id>NCT02572817</nct_id>
    <nct_alias>NCT02610478</nct_alias>
  </id_info>
  <brief_title>Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A</brief_title>
  <official_title>A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition
      to standard of care antivirals, in participants hospitalized with severe influenza A
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite antivirals and vaccines, influenza is responsible for thousands of hospitalizations
      and deaths each year worldwide. Because of this, additional treatments for influenza are
      needed. One potential treatment may be the use of high-titer anti-influenza immune plasma.
      The purpose of this study is to evaluate the efficacy and safety of treatment with high-titer
      versus low-titer anti-influenza immune plasma, in addition to standard care, in participants
      hospitalized with severe influenza A infection.

      This study enrolled people aged 2 weeks or older who are hospitalized with severe influenza A
      infection. Participants were randomly assigned to receive either high-titer anti-influenza
      plasma or low-titer (control) anti-influenza plasma on Day 0. In addition, all participants
      received standard care antivirals. Participants were assessed on Day 0 (baseline) and on Days
      1, 2, 3, 7, 14, and 28. For participants who were not hospitalized on Days 2, 14, and 28,
      researchers could contact participants by telephone. Study procedures included clinical
      assessments, blood collection, and oropharyngeal swabs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 26, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Status at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The clinical status at Day 7 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The clinical status at Day 1 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status at Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>The clinical status at Day 2 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status at Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>The clinical status at Day 3 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>The clinical status at Day 14 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>The clinical status at Day 28 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Initial Hospitalization</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Duration (in days) of initial hospitalization, restricted to duration between randomization and last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Number of deaths during study follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality During Initial Hospitalization</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Number of deaths in the hospital during initial hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Mortality and Hospitalization at Day 7, Day 14, Day 28</measure>
    <time_frame>Day 7, Day 14, Day 28</time_frame>
    <description>Two categories were considered for the composite of mortality and hospitalization:
Dead or hospitalized Alive and not hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 3 and Day 7 in National Early Warning (NEW) Score</measure>
    <time_frame>Day 0, Day 3, Day 7</time_frame>
    <description>The National Early Warning (NEW) score was only measured for the adult participants.
The range of the NEW score is from 0 to 20, with lower values representing a better outcome.
Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 3 and Day 7 in Pediatric Early Warning (PEW) Score</measure>
    <time_frame>Day 0, Day 3, Day 7</time_frame>
    <description>The Pediatric Early Warning (PEW) score was only measured for the pediatric participants.
The range is from 0 to 26, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>From Day 0 to Day 28 visit. The window of the Day 28 visit was 28-32 days from study entry.</time_frame>
    <description>Duration (in days) of total supplemental oxygen use among those participants who required new or increased oxygen at randomization.
The duration is restricted to duration between randomization and last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Oxygen Use During the Study</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Incidence of new oxygen use during the study among those participants who did not require oxygen at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Duration (in days) of ICU stay among those participants who were in ICU at randomization.
The duration is restricted to duration between randomization and last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New ICU Admission Use During the Study</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Incidence of new ICU admission during the study among those participants who were not in ICU at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation Use</measure>
    <time_frame>From Day 0 to Day 28 visit. The window of the Day 28 visit was 28-32 days from study entry</time_frame>
    <description>Duration (in days) of mechanical ventilation use among those participants who were on mechanical ventilation at randomization.
The duration is restricted to duration between randomization and last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Mechanical Ventilation Use Stay Use During the Study</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Incidence of new mechanical ventilation use during the study among those participants who were not on mechanical ventilation at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Duration (in days) of ARDS use among those participants with ARDS at randomization.
The duration is restricted to duration between randomization and last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New ARDS During the Study</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Incidence of new ARDS during the study among those participants without ARDS at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Duration (in days) of ECMO use among those participants on ECMO at randomization.
The duration is restricted to duration between randomization and last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New ECMO Use During the Study</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Incidence of new ECMO use during the study among those participants not on ECMO at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 3 and Day 7 in Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Day 0, Day 3, Day 7</time_frame>
    <description>The Sequential Organ Failure Assessment (SOFA) score was only measured for the adult participants.
The range is from 0 to 24, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 3 and Day 7 in Pediatric Logistic Organ Dysfunction (PELOD) Score</measure>
    <time_frame>Day 0, Day 3, Day 7</time_frame>
    <description>The Pediatric Logistic Organ Dysfunction (PELOD) score was only measured for the pediatric participants.
The range is from 0 to 71, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition After Initial Hospitalization</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Disposition at discharge after initial hospitalization was categorized as follows:
Death, Ongoing at 28 days, Chronic nursing facility, Rehabilitation, Home with home health care, Home without assistance.
The number of deaths at discharge after initial hospitalization do not necessarily match the overall number of deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable Influenza Virus at Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Detectable influenza virus at Day 3 in oropharyngeal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/H1N1</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/H1N1. HAI for A/H1N1 was tested in all influenza seasons while the study was ongoing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2. HAI for A/HongKong/4801/2014 H3N2 was tested in all influenza seasons while the study was ongoing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 and 4 Adverse Events (AEs).</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Number of participants with reported grade 3 and 4 adverse events (AEs) throughout the study duration. In cases where participants had multiple reports of grade 3 and 4 AEs, they were only counted once.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs).</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Number of participants with reported serious adverse events (SAEs) throughout the study duration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Influenza A Virus Infection</condition>
  <arm_group>
    <arm_group_label>High-titer anti-influenza plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-titer anti-influenza plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-titer anti-influenza plasma</intervention_name>
    <description>Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80</description>
    <arm_group_label>High-titer anti-influenza plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-titer anti-influenza plasma</intervention_name>
    <description>Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less</description>
    <arm_group_label>Low-titer anti-influenza plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Enrollment (Screening):

          -  Subjects must be aged 2 weeks or older.

          -  Hospitalization due to signs and symptoms of influenza.

             * Note: The decision for hospitalization will be made by the treating clinician. To be
             considered eligible, the hospitalization may either be an initial hospitalization, or
             a prolongation of a hospitalization due to a respiratory illness that was found to be
             from influenza. Influenza could be a component of a larger respiratory syndrome (i.e.
             COPD exacerbation thought to be triggered by influenza). However, respiratory
             syndromes that are not likely due to the virus should not be included (i.e. a subject
             that had mild influenza then developed pulmonary embolism and respiratory distress
             from the embolism).

          -  Study plasma available on-site or available within 24 hours after randomization.

          -  Not previously screened nor randomized in this study.

          -  Willingness to have blood and respiratory samples obtained and stored.

          -  Willingness to return for all required study visits and participate in study follow
             up.

        Inclusion Criteria for Randomization:

          -  Locally determined positive test for influenza A (by polymerase chain reaction [PCR],
             other nucleic acid testing, or by rapid Ag) from a specimen obtained less than or
             equal to 48 hours prior to randomization.

          -  Onset of illness less than or equal to 6 days before randomization, defined as when
             the subject first experienced at least one respiratory symptom or fever.

          -  Note: For subjects with chronic respiratory symptoms (chronic cough, or COPD with
             baseline dyspnea), the onset of symptoms is defined as the point when the symptoms
             changed during this illness). Hospitalized due to influenza, with anticipated
             hospitalization for more than 24 hours after randomization. Criteria for
             hospitalization will be up to the individual treating clinician.

          -  National Early Warning (NEW) or Pediatric Early Warning (PEW) score greater than or
             equal to 3 within 12 hours prior to randomization.

          -  ABO-compatible plasma available on-site or available within 24 hours after
             randomization.

        Exclusion Criteria for Randomization:

          -  Strong clinical evidence in the judgment of the site investigator that the etiology of
             illness is primarily bacterial super-infection in origin. Co-infection would be
             allowed, as there may be benefit to resolving influenza illness faster.
             Super-infection, where influenza illness occurred and is resolving, and new bacterial
             illness causing deterioration should be excluded (e.g., if the subject's respiratory
             infection is thought unlikely to benefit from additional antiviral therapy, this
             exclusion criteria would be met).

          -  Prior treatment with any anti-influenza investigational drug, anti-influenza
             investigational intravenous immune globulin (IVIG), or anti-influenza investigational
             plasma therapy within 30 days prior to screening. Other investigational drug therapies
             (non-influenza) and administration of plasma and/or IVIG for non-influenza reasons are
             allowed.

          -  History of allergic reaction to blood or plasma products (as judged by the site
             investigator).

          -  A pre-existing condition or use of a medication that, in the opinion of the site
             investigator, may place the individual at a substantially increased risk of thrombosis
             (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically
             significant monoclonal gammopathy). Prior IVIG use alone would not meet exclusion
             criteria, but the investigator should consider the potential for a hyper-coagulable
             state.

          -  Subjects who, in the judgment of the site investigator, will be unlikely to comply
             with the requirements of this protocol, including being not contactable following
             discharge from hospital.

          -  Medical conditions for which receipt of 500-600 mL (or pediatric equivalent) of
             intravenous fluid may be dangerous to the subject (e.g., decompensated congestive
             heart failure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beigel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Pediatrics Infectious Diseases</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego (NMCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Campus Saint Mary's</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital at Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University/Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center (MAMC)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &quot;sepsis-related problems&quot; of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800.</citation>
    <PMID>9824069</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.</citation>
    <PMID>8844239</PMID>
  </reference>
  <reference>
    <citation>Leteurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F. Paediatric logistic organ dysfunction (PELOD) score. Lancet. 2006 Mar 18;367(9514):897; author reply 900-2.</citation>
    <PMID>16546531</PMID>
  </reference>
  <reference>
    <citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, Gottesman R, Joffe A, Pfenninger J, Hubert P, Lacroix J, Leclerc F. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003 Jul 19;362(9379):192-7. Erratum in: Lancet. 2006 Mar 18;367(9514):902. Erratum in: Lancet. 2006 Mar 18;367(9514):897; author reply 900-2.</citation>
    <PMID>12885479</PMID>
  </reference>
  <reference>
    <citation>Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013 Apr;84(4):465-70. doi: 10.1016/j.resuscitation.2012.12.016. Epub 2013 Jan 4.</citation>
    <PMID>23295778</PMID>
  </reference>
  <reference>
    <citation>Parshuram CS, Bayliss A, Reimer J, Middaugh K, Blanchard N. Implementing the Bedside Paediatric Early Warning System in a community hospital: A prospective observational study. Paediatr Child Health. 2011 Mar;16(3):e18-22.</citation>
    <PMID>22379384</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>May 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2019</results_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Influenza Immune Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02572817/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02572817/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-titer Anti-influenza Plasma mITT</title>
          <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
        <group group_id="P2">
          <title>Low-titer Anti-influenza Plasma mITT</title>
          <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-titer Anti-influenza Plasma mITT</title>
          <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
        <group group_id="B2">
          <title>Low-titer Anti-influenza Plasma mITT</title>
          <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="47" upper_limit="69"/>
                    <measurement group_id="B2" value="63" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B3" value="61" lower_limit="45" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline National Early Warning (NEW) score</title>
          <description>The National Early Warning (NEW) score was only measured for the adult participants. The NEW score is used to determine the degree of illness of a patient. Baseline is defined as the Day 0. The NEW score is based on 7 clinical parameters. The total score is reported. The range is from 0 to 20, with lower values representing a better outcome. For more details see protocol section 7.3.2.</description>
          <population>The NEW score was only measured for the adult participants. Only non-missing scores were summarized.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B2" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B3" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pediatric Early Warning (PEW) score</title>
          <description>The Pediatric Early Warning (PEW) score was only measured for the pediatric participants. The PEW score is a numerical scoring system to define pediatric patients at risk of clinical deterioration. Baseline is defined as the Day 0. The PEW score is based on 7 clinical parameters. The total score is reported. The range is from 0 to 26, with lower values representing a better outcome. For more details see protocol section 7.3.3.</description>
          <population>The PEW score was only measured for the pediatric participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="5" upper_limit="11.5"/>
                    <measurement group_id="B2" value="8" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="B3" value="8" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>The Sequential Organ Failure Assessment (SOFA) score was only measured for the adult participants. The SOFA score is a scoring system to determine the extent of a person's organ function or rate of failure. Baseline is defined as the Day 0. The SOFA score is based on six different scores. The total score is reported. The range is from 0 to 24, with lower values representing a better outcome. For more details see protocol section 7.3.4.</description>
          <population>The SOFA score was only measured for the adult participants. Only non-missing scores were summarized.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="B2" value="3" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="B3" value="3" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pediatric Logistic Organ Dysfunction (PELOD) Score</title>
          <description>The Pediatric Logistic Organ Dysfunction (PELOD) score was only measured for the pediatric participants. The PELOD score is an organ dysfunction score that can be used in the pediatric population to sequentially evaluate organ dysfunction and predict mortality. Baseline is defined as the Day 0. The score is based on six different scores. The total score is reported. The range is from 0 to 71, with lower values representing a better outcome. For more details see protocol section 7.3.5.</description>
          <population>The PELOD score was only measured for the pediatric participants. Only non-missing scores were summarized.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B2" value="3" lower_limit="1.5" upper_limit="12"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Status at Day 7</title>
        <description>The clinical status at Day 7 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 7</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment (with available data).</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 7</title>
          <description>The clinical status at Day 7 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment (with available data).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status at Day 1</title>
        <description>The clinical status at Day 1 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 1</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 1</title>
          <description>The clinical status at Day 1 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status at Day 2</title>
        <description>The clinical status at Day 2 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 2</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 2</title>
          <description>The clinical status at Day 2 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status at Day 3</title>
        <description>The clinical status at Day 3 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 3</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 3</title>
          <description>The clinical status at Day 3 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status at Day 14</title>
        <description>The clinical status at Day 14 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 14</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 14</title>
          <description>The clinical status at Day 14 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status at Day 28</title>
        <description>The clinical status at Day 28 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
        <time_frame>Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status at Day 28</title>
          <description>The clinical status at Day 28 was based on a 6-point ordinal scale:
Death
In ICU
Non-ICU hospitalization, requiring supplemental oxygen (O2)
Non-ICU hospitalization, not requiring supplemental oxygen
Not hospitalized, but unable to resume normal activities
Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization with supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization without supplemental O2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, unable for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized, able for normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Initial Hospitalization</title>
        <description>Duration (in days) of initial hospitalization, restricted to duration between randomization and last visit</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Initial Hospitalization</title>
          <description>Duration (in days) of initial hospitalization, restricted to duration between randomization and last visit</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Mortality</title>
        <description>Number of deaths during study follow-up</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>Number of deaths during study follow-up</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality During Initial Hospitalization</title>
        <description>Number of deaths in the hospital during initial hospitalization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Mortality During Initial Hospitalization</title>
          <description>Number of deaths in the hospital during initial hospitalization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Mortality and Hospitalization at Day 7, Day 14, Day 28</title>
        <description>Two categories were considered for the composite of mortality and hospitalization:
Dead or hospitalized Alive and not hospitalized</description>
        <time_frame>Day 7, Day 14, Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Mortality and Hospitalization at Day 7, Day 14, Day 28</title>
          <description>Two categories were considered for the composite of mortality and hospitalization:
Dead or hospitalized Alive and not hospitalized</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite mortality and hospitalization, Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Dead or hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive and not hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite mortality and hospitalization, Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Dead or hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive and not hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite mortality and hospitalization, Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Dead or hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alive and not hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Composite mortality and hospitalization, Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Composite mortality and hospitalization, Day 14</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Composite mortality and hospitalization, Day 28</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>4.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 3 and Day 7 in National Early Warning (NEW) Score</title>
        <description>The National Early Warning (NEW) score was only measured for the adult participants.
The range of the NEW score is from 0 to 20, with lower values representing a better outcome.
Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
        <time_frame>Day 0, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat adult population: subgroup of randomized adult participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 3 and Day 7 in National Early Warning (NEW) Score</title>
          <description>The National Early Warning (NEW) score was only measured for the adult participants.
The range of the NEW score is from 0 to 20, with lower values representing a better outcome.
Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
          <population>Modified intent-to-treat adult population: subgroup of randomized adult participants who received any study treatment</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in NEW from baseline to Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in NEW from baseline to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="-2" lower_limit="-4" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in NEW from baseline to Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in NEW from baseline to Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 3 and Day 7 in Pediatric Early Warning (PEW) Score</title>
        <description>The Pediatric Early Warning (PEW) score was only measured for the pediatric participants.
The range is from 0 to 26, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
        <time_frame>Day 0, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat pediatric population: subgroup of randomized pediatric participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 3 and Day 7 in Pediatric Early Warning (PEW) Score</title>
          <description>The Pediatric Early Warning (PEW) score was only measured for the pediatric participants.
The range is from 0 to 26, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
          <population>Modified intent-to-treat pediatric population: subgroup of randomized pediatric participants who received any study treatment</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PEW from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-3" upper_limit="2"/>
                    <measurement group_id="O2" value="-1" lower_limit="-6" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in PEW from baseline to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-7" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-5" lower_limit="-8" upper_limit="-3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PEW from baseline to Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PEW from baseline to Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Supplemental Oxygen</title>
        <description>Duration (in days) of total supplemental oxygen use among those participants who required new or increased oxygen at randomization.
The duration is restricted to duration between randomization and last visit.</description>
        <time_frame>From Day 0 to Day 28 visit. The window of the Day 28 visit was 28-32 days from study entry.</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who required new or increased oxygen at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen</title>
          <description>Duration (in days) of total supplemental oxygen use among those participants who required new or increased oxygen at randomization.
The duration is restricted to duration between randomization and last visit.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who required new or increased oxygen at randomization.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="21"/>
                    <measurement group_id="O2" value="7" lower_limit="3" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Oxygen Use During the Study</title>
        <description>Incidence of new oxygen use during the study among those participants who did not require oxygen at randomization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who did not require oxygen at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Oxygen Use During the Study</title>
          <description>Incidence of new oxygen use during the study among those participants who did not require oxygen at randomization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who did not require oxygen at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>11.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Intensive Care Unit (ICU) Stay</title>
        <description>Duration (in days) of ICU stay among those participants who were in ICU at randomization.
The duration is restricted to duration between randomization and last visit.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were in the ICU at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intensive Care Unit (ICU) Stay</title>
          <description>Duration (in days) of ICU stay among those participants who were in ICU at randomization.
The duration is restricted to duration between randomization and last visit.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were in the ICU at randomization.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3.5" upper_limit="12.5"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New ICU Admission Use During the Study</title>
        <description>Incidence of new ICU admission during the study among those participants who were not in ICU at randomization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not in the ICU at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New ICU Admission Use During the Study</title>
          <description>Incidence of new ICU admission during the study among those participants who were not in ICU at randomization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not in the ICU at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation Use</title>
        <description>Duration (in days) of mechanical ventilation use among those participants who were on mechanical ventilation at randomization.
The duration is restricted to duration between randomization and last visit.</description>
        <time_frame>From Day 0 to Day 28 visit. The window of the Day 28 visit was 28-32 days from study entry</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were on mechanical ventilation at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation Use</title>
          <description>Duration (in days) of mechanical ventilation use among those participants who were on mechanical ventilation at randomization.
The duration is restricted to duration between randomization and last visit.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were on mechanical ventilation at randomization.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="O2" value="15.5" lower_limit="7" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Mechanical Ventilation Use Stay Use During the Study</title>
        <description>Incidence of new mechanical ventilation use during the study among those participants who were not on mechanical ventilation at randomization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not on mechanical ventilation at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Mechanical Ventilation Use Stay Use During the Study</title>
          <description>Incidence of new mechanical ventilation use during the study among those participants who were not on mechanical ventilation at randomization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not on mechanical ventilation at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>9.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Acute Respiratory Distress Syndrome (ARDS)</title>
        <description>Duration (in days) of ARDS use among those participants with ARDS at randomization.
The duration is restricted to duration between randomization and last visit.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants with ARDS at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Acute Respiratory Distress Syndrome (ARDS)</title>
          <description>Duration (in days) of ARDS use among those participants with ARDS at randomization.
The duration is restricted to duration between randomization and last visit.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants with ARDS at randomization.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="15"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New ARDS During the Study</title>
        <description>Incidence of new ARDS during the study among those participants without ARDS at randomization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants without ARDS at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New ARDS During the Study</title>
          <description>Incidence of new ARDS during the study among those participants without ARDS at randomization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants without ARDS at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Extracorporeal Membrane Oxygenation (ECMO)</title>
        <description>Duration (in days) of ECMO use among those participants on ECMO at randomization.
The duration is restricted to duration between randomization and last visit.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were on ECMO at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Extracorporeal Membrane Oxygenation (ECMO)</title>
          <description>Duration (in days) of ECMO use among those participants on ECMO at randomization.
The duration is restricted to duration between randomization and last visit.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were on ECMO at randomization.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="O2" value="20" lower_limit="20" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New ECMO Use During the Study</title>
        <description>Incidence of new ECMO use during the study among those participants not on ECMO at randomization</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not on ECMO at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New ECMO Use During the Study</title>
          <description>Incidence of new ECMO use during the study among those participants not on ECMO at randomization</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment, further subset to those participants who were not on ECMO at randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 3 and Day 7 in Sequential Organ Failure Assessment (SOFA) Score</title>
        <description>The Sequential Organ Failure Assessment (SOFA) score was only measured for the adult participants.
The range is from 0 to 24, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
        <time_frame>Day 0, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat adult population: subgroup of randomized adult participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 3 and Day 7 in Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>The Sequential Organ Failure Assessment (SOFA) score was only measured for the adult participants.
The range is from 0 to 24, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
          <population>Modified intent-to-treat adult population: subgroup of randomized adult participants who received any study treatment.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SOFA from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SOFA from baseline to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SOFA from baseline to Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SOFA from baseline to Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman estimate of location shift</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 3 and Day 7 in Pediatric Logistic Organ Dysfunction (PELOD) Score</title>
        <description>The Pediatric Logistic Organ Dysfunction (PELOD) score was only measured for the pediatric participants.
The range is from 0 to 71, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
        <time_frame>Day 0, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat pediatric population: subgroup of randomized pediatric participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 3 and Day 7 in Pediatric Logistic Organ Dysfunction (PELOD) Score</title>
          <description>The Pediatric Logistic Organ Dysfunction (PELOD) score was only measured for the pediatric participants.
The range is from 0 to 71, with lower values representing a better outcome. Baseline is defined as the Day 0. Change was defined as the value at Day 3 or Day 7 minus the value at baseline.</description>
          <population>Modified intent-to-treat pediatric population: subgroup of randomized pediatric participants who received any study treatment</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in PELOD from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in PELOD from baseline to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="0" lower_limit="-1.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PELOD from baseline to Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PELOD from baseline to Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition After Initial Hospitalization</title>
        <description>Disposition at discharge after initial hospitalization was categorized as follows:
Death, Ongoing at 28 days, Chronic nursing facility, Rehabilitation, Home with home health care, Home without assistance.
The number of deaths at discharge after initial hospitalization do not necessarily match the overall number of deaths.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition After Initial Hospitalization</title>
          <description>Disposition at discharge after initial hospitalization was categorized as follows:
Death, Ongoing at 28 days, Chronic nursing facility, Rehabilitation, Home with home health care, Home without assistance.
The number of deaths at discharge after initial hospitalization do not necessarily match the overall number of deaths.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ongoing at 28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic nursing facility/</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rehabilitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home with home health care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home without assistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detectable Influenza Virus at Day 3</title>
        <description>Detectable influenza virus at Day 3 in oropharyngeal samples</description>
        <time_frame>Day 3</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment. This group was further subset wo those with available OP sample results at Day 3.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Influenza Virus at Day 3</title>
          <description>Detectable influenza virus at Day 3 in oropharyngeal samples</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment. This group was further subset wo those with available OP sample results at Day 3.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Undetectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/H1N1</title>
        <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/H1N1. HAI for A/H1N1 was tested in all influenza seasons while the study was ongoing.</description>
        <time_frame>Day 1, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/H1N1</title>
          <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/H1N1. HAI for A/H1N1 was tested in all influenza seasons while the study was ongoing.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="38.5" upper_limit="57.1"/>
                    <measurement group_id="O2" value="19.7" lower_limit="13.9" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" lower_limit="40.9" upper_limit="62.6"/>
                    <measurement group_id="O2" value="23.7" lower_limit="16.7" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" lower_limit="49.5" upper_limit="80.6"/>
                    <measurement group_id="O2" value="37.1" lower_limit="23.2" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2</title>
        <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2. HAI for A/HongKong/4801/2014 H3N2 was tested in all influenza seasons while the study was ongoing.</description>
        <time_frame>Day 1, Day 3, Day 7</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition Assay (HAI) Titers at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2</title>
          <description>Hemagglutination inhibition assay (HAI) titers as measured by serial dilutions at Days 1, 3, 7 for A/HongKong/4801/2014 H3N2. HAI for A/HongKong/4801/2014 H3N2 was tested in all influenza seasons while the study was ongoing.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment</population>
          <units>ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="43.2" upper_limit="66.7"/>
                    <measurement group_id="O2" value="22.4" lower_limit="16.6" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="44" upper_limit="69.4"/>
                    <measurement group_id="O2" value="36.8" lower_limit="24.6" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="57.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="53" lower_limit="30.9" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 and 4 Adverse Events (AEs).</title>
        <description>Number of participants with reported grade 3 and 4 adverse events (AEs) throughout the study duration. In cases where participants had multiple reports of grade 3 and 4 AEs, they were only counted once.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 and 4 Adverse Events (AEs).</title>
          <description>Number of participants with reported grade 3 and 4 adverse events (AEs) throughout the study duration. In cases where participants had multiple reports of grade 3 and 4 AEs, they were only counted once.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs).</title>
        <description>Number of participants with reported serious adverse events (SAEs) throughout the study duration.</description>
        <time_frame>From Day 0 to Day 28</time_frame>
        <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>High-titer Anti-influenza Plasma mITT</title>
            <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
          <group group_id="O2">
            <title>Low-titer Anti-influenza Plasma mITT</title>
            <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs).</title>
          <description>Number of participants with reported serious adverse events (SAEs) throughout the study duration.</description>
          <population>Modified intent-to-treat population: subgroup of randomized participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry (Day 0) to Day 28</time_frame>
      <desc>The protocol required reporting of all grade 3 and 4 adverse events (AEs), all serious AEs and any AE leading to plasma discontinuation (regardless of grade). Clinically evident diagnoses were recorded as AEs. All worsening laboratory values were evaluated as potential AEs. The grading reference was the &quot;Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events&quot; Version 2.0, November 2014.</desc>
      <group_list>
        <group group_id="E1">
          <title>High-titer Anti-influenza Plasma mITT</title>
          <description>High-titer anti-influenza mITT (modified intent to treat) is the subgroup of high-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
        <group group_id="E2">
          <title>Low-titer Anti-influenza Plasma mITT</title>
          <description>Low-titer anti-influenza mITT (modified intent to treat) is the subgroup of low-titer anti-influenza plasma participants who received any study plasma</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Transfusion-related circulatory overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma refractory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Beigel, M.D.</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases (NIAID)</organization>
      <phone>301-451-9881</phone>
      <email>jbeigel@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

